According to Coherent Market Insights, the global chronic kidney disease drugs market is estimated to be valued at US$ 13,220.0 million in 2022 and is expected to exhibit a CAGR of 4.5% during the forecast period (2022-2030).
Increasing prevalence of chronic kidney disease is expected to drive the growth of the global chronic kidney disease drugs market. For instance, according to an article published by the University of Tennessee Health Science Center, U.S. in November 2021, an estimated prevalence of chronic kidney disease by age-standardized prevalence is 8.6% and 9.6% in men and women, respectively, in high-income countries, and 10.6% and 12.5% in men and women, respectively, in low- and middle-income countries. The global age-standardized prevalence of CKD stages 1–5 in individuals aged 20 years of 10.4% among men and 11.8% among women.